Oncologic Efficacy of Wedge Resection, Segmentectomy, and Lobectomy in Real-World Clinical Settings Versus Clinical Trial Settings: Key Considerations and Lessons Learned [0.03%]
真实世界与临床试验中局部亚肺切除与肺叶切除的疗效对比：关键考量及经验教训
Alexandra L Potter,Alexander Zhu,Chi-Fu Jeffrey Yang
Alexandra L Potter
Lung Cancer in Jordan [0.03%]
约旦的肺癌患者
Kamal Al-Rabi,Osama El Khatib,Raid Abdeljalil et al.
Kamal Al-Rabi et al.
A Novel Strategy to Optimize Surgical Outcomes in Thymoma-Associated Myasthenia Gravis: Perioperative Use of Efgartigimod [0.03%]
胸腺瘤相关重症肌无力围手术期使用Efgartigimod优化外科治疗效果的新策略
Tomoyuki Hishida
Tomoyuki Hishida
Paul Van Houtte,Luigi Moretti
Paul Van Houtte
SUPE_R Surveillance? PET/CT in Post-Treatment NSCLC and the Imperative of Proof Before Practice [0.03%]
PET/CT在非小细胞肺癌术后应用的证据与实践问题
Rajat Thawani,Naga Praneeth Raja,Jeremy Cetnar
Rajat Thawani
Digital Versus Manual PD-L1 Scoring in Advanced Non-Small Cell Lung Cancer From the IMpower110 and IMpower150 Trials [0.03%]
来自IMpower110和IMpower150试验的晚期非小细胞肺癌的数字与手动PD-L1评分法比较
Roy S Herbst,Hen Prizant,Daniel Ruderman et al.
Roy S Herbst et al.
Introduction: Treatment selection in patients with advanced non-small cell lung cancer (NSCLC) is based on programmed death-ligand 1 (PD-L1) expression, which is usually scored manually and is subject to intra-/inter-path...
Molecular Landscape and Therapeutic Strategies of Lung Cancer Lineage Plasticity [0.03%]
肺癌谱系转换的分子特征及治疗策略研究进展
Avisek Banerjee,Ioannis Vathiotis,Debdatta Halder et al.
Avisek Banerjee et al.
Histologic transformation from lung adenocarcinoma (LUAD) to SCLC or lung squamous cell carcinoma (LUSC) represents distinct but converging processes of cellular plasticity. Cellular plasticity, the ability to switch phenotypes between dist...
Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small cell lung cancer [0.03%]
DESTINY-Lung02研究最终分析结果和患者报告结局：在HER2突变转移性非小细胞肺癌患者中开展的曲妥珠单抗德鲁替康与多西他赛随机Ⅱ期临床试验剂量盲态评估
Pasi A Jänne,Yasushi Goto,Toshio Kubo et al.
Pasi A Jänne et al.
Introduction: Trastuzumab deruxtecan (T-DXd) demonstrated strong and durable responses in patients with previously treated human epidermal growth factor receptor 2 (HER2;ERBB2)-mutant (HER2m) metastatic non-small cell lun...
Brief Report: Comprehensive Genomic Profiling of Rare Lung Tumors: Adenosquamous Carcinoma and Pulmonary Carcinosarcoma [0.03%]
简报：罕见肺肿瘤的全面基因组特征分析：腺鳞癌和肺类癌肉瘤
Tianhao Zhou,Olivia C Terry,Katherine G Minton et al.
Tianhao Zhou et al.
In 2025, lung cancer remains the leading cause of cancer-related mortality in both men and women. While the advent of immunotherapy and targeted therapies have revolutionized the treatment of non-small cell lung cancer (NSCLC), treatments f...
Distinct Clinicogenomic Features and Immunotherapy Associations in Pulmonary Sarcomatoid Carcinoma: A Multi-Center Retrospective Study [0.03%]
pulmonary sarcomatoid carcinoma的临床基因组特征及免疫治疗相关性：一项多中心回顾性研究
Lingzhi Hong,Alessandro Di Federico,Bolun Liu et al.
Lingzhi Hong et al.
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare non-small cell lung cancer (NSCLC) subtype with poor prognosis. Outcomes to immune checkpoint inhibitors (ICIs) and genomic features in PSC remain underexplored ...